177 related articles for article (PubMed ID: 38006567)
1. Clinical outcomes of Epstein-Barr virus (EBV)-associated metastatic and locally advanced unresectable gastric cancers (GCs) in patients receiving first-line fluoropyrimidine and platinum (FP) doublet chemotherapy.
Kim EJ; Chae H; Park YS; Ryu MH; Kim HD; Shin J; Park YS; Moon MS; Kang YK
Gastric Cancer; 2024 Jan; 27(1):146-154. PubMed ID: 38006567
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological characteristics and prognosis of Epstein-Barr virus-associated gastric cancer.
Li LL; Yu AY; Zhu M; Ma LY; Cao MH; Liu WL; Qin XB; Gao C; Han ZX; Wang HM
Arch Virol; 2024 May; 169(5):114. PubMed ID: 38700535
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and predictive biomarkers of immunotherapy in Epstein-Barr virus-associated gastric cancer.
Bai Y; Xie T; Wang Z; Tong S; Zhao X; Zhao F; Cai J; Wei X; Peng Z; Shen L
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35241494
[TBL] [Abstract][Full Text] [Related]
4. Clinical Behavior and Treatment Response of Epstein-Barr Virus-Positive Metastatic Gastric Cancer: Implications for the Development of Future Trials.
Corallo S; Fucà G; Morano F; Salati M; Spallanzani A; Gloghini A; Volpi CC; Trupia DV; Lobefaro R; Guarini V; Milione M; Cattaneo L; Antista M; Prisciandaro M; Raimondi A; Sposito C; Mazzaferro V; de Braud F; Pietrantonio F; Di Bartolomeo M
Oncologist; 2020 Sep; 25(9):780-786. PubMed ID: 32272500
[TBL] [Abstract][Full Text] [Related]
5. Clinical utility of circulating cell-free Epstein-Barr virus DNA in patients with gastric cancer.
Shoda K; Ichikawa D; Fujita Y; Masuda K; Hiramoto H; Hamada J; Arita T; Konishi H; Kosuga T; Komatsu S; Shiozaki A; Okamoto K; Imoto I; Otsuji E
Oncotarget; 2017 Apr; 8(17):28796-28804. PubMed ID: 28430637
[TBL] [Abstract][Full Text] [Related]
6. Prevalence and characteristics of Epstein-Barr virus associated gastric carcinoma in Gansu Province, Northwest China with mRNA expression of glycoprotein BMRF2.
Guo C; Wei J; Scott RS; Chen Y; Chen Z; Zhao W; Zhang C; Wang B; Chai C; Dai G; Li M; Zhang F
J Med Virol; 2020 Mar; 92(3):356-363. PubMed ID: 31663617
[TBL] [Abstract][Full Text] [Related]
7. Sex-dependent different clinicopathological characterization of Epstein-Barr virus-associated gastric carcinoma: a large-scale study.
Kim JH; Kim N; Song DH; Choi Y; Jeon EB; Kim S; Jun YK; Yoon H; Shin CM; Park YS; Lee DH; Oh HJ; Lee HS; Park YS; Ahn SH; Suh YS; Park DJ; Kim HH; Kim JW; Kim JW; Lee KW; Chang W; Park JH; Lee YJ; Lee KH; Kim YH; Ahn S
Gastric Cancer; 2024 Mar; 27(2):221-234. PubMed ID: 38212543
[TBL] [Abstract][Full Text] [Related]
8. Clinical and pathological characterization of Epstein-Barr virus-associated gastric carcinomas in Portugal.
Ribeiro J; Oliveira A; Malta M; Oliveira C; Silva F; Galaghar A; Afonso LP; Neves MC; Medeiros R; Pimentel-Nunes P; Sousa H
World J Gastroenterol; 2017 Oct; 23(40):7292-7302. PubMed ID: 29142476
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of spasmolytic polypeptide-expressing metaplasia and intestinal metaplasia in Epstein-Barr virus-associated and Epstein-Barr virus-negative gastric cancer.
Zhang Y; Chen JN; Dong M; Zhang ZG; Zhang YW; Wu JY; Du H; Li HG; Huang Y; Shao CK
Hum Pathol; 2017 May; 63():128-138. PubMed ID: 28300576
[TBL] [Abstract][Full Text] [Related]
10. Epstein-Barr Virus Positive Gastric Cancer: A Distinct Subtype Candidate for Immunotherapy.
Pereira MA; Batista DAM; Ramos MFKP; Cardili L; Ribeiro RRE; Dias AR; Zilberstein B; Ribeiro U; Cecconello I; Alves VAF; Mello ES
J Surg Res; 2021 May; 261():130-138. PubMed ID: 33429221
[TBL] [Abstract][Full Text] [Related]
11. Case report: Long response to PD-1 blockade after failure of trastuzumab plus chemotherapy in advanced Epstein-Barr virus-associated gastric cancer.
Pan Y; Lu L; Liu H; Chen D; Han N; Yao R; Wang X; Gao X; Yu J; Chen L; Zhou F; Hao G; Lu Y; Li M; He G; Kang F; Li Z; Tang Y; Zhang J; Wei L; Nie Y
Front Immunol; 2022; 13():1003859. PubMed ID: 36353623
[TBL] [Abstract][Full Text] [Related]
12. Epstein-Barr virus-associated gastric carcinoma and Epstein-Barr virus infection of the stomach.
Fukayama M; Hayashi Y; Iwasaki Y; Chong J; Ooba T; Takizawa T; Koike M; Mizutani S; Miyaki M; Hirai K
Lab Invest; 1994 Jul; 71(1):73-81. PubMed ID: 8041121
[TBL] [Abstract][Full Text] [Related]
13. EBNA1 inhibitors have potent and selective antitumor activity in xenograft models of Epstein-Barr virus-associated gastric cancer.
Soldan SS; Anderson EM; Frase DM; Zhang Y; Caruso LB; Wang Y; Deakyne JS; Gewurz BE; Tempera I; Lieberman PM; Messick TE
Gastric Cancer; 2021 Sep; 24(5):1076-1088. PubMed ID: 33929613
[TBL] [Abstract][Full Text] [Related]
14. Prospective observation: Clinical utility of plasma Epstein-Barr virus DNA load in EBV-associated gastric carcinoma patients.
Qiu MZ; He CY; Lu SX; Guan WL; Wang F; Wang XJ; Jin Y; Wang FH; Li YH; Shao JY; Zhou ZW; Yun JP; Xu RH
Int J Cancer; 2020 Jan; 146(1):272-280. PubMed ID: 31162842
[TBL] [Abstract][Full Text] [Related]
15. The importance of Epstein-Barr virus infection in the systemic treatment of patients with gastric cancer.
Pikuła A; Kwietniewska M; Rawicz-Pruszyński K; Ciseł B; Skórzewska M; Gęca K; Franciszkiewicz-Pietrzak K; Kurylcio A; Mielko J; Polkowski WP
Semin Oncol; 2020; 47(2-3):127-137. PubMed ID: 32402473
[TBL] [Abstract][Full Text] [Related]
16. Epstein-Barr Virus Infection in Gastric Remnant Carcinoma and Recurrent Gastric Carcinoma in Qingdao of Northern China.
Liu S; Zhao Z; Han L; Liu S; Luo B
PLoS One; 2016; 11(2):e0148342. PubMed ID: 26859565
[TBL] [Abstract][Full Text] [Related]
17. Deletion of Epstein-Barr virus latent membrane protein 1 gene in Japanese and Brazilian gastric carcinomas, metastatic lesions, and reactive lymphocytes.
Hayashi K; Chen WG; Chen YY; Murakami I; Chen HL; Ohara N; Nose S; Hamaya K; Matsui S; Bacchi MM; Bacchi CE; Chang KL; Weiss LM
Am J Pathol; 1998 Jan; 152(1):191-8. PubMed ID: 9422536
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Perspectives of STING and PD-L1 Expression and Correlation with the Prognosis of Epstein-Barr Virus-Associated Gastric Cancers.
Sun Q; Fu Y; Chen X; Li L; Wu H; Liu Y; Xu H; Zhou G; Fan X; Xia H
Gut Liver; 2022 Nov; 16(6):875-891. PubMed ID: 35611665
[TBL] [Abstract][Full Text] [Related]
19. Distribution of the Epstein-Barr virus in the normal stomach and gastric lesions in Thai population.
Wanvimonsuk S; Thitiwanichpiwong P; Keelawat S; Mutirangura A; Kitkumthorn N
J Med Virol; 2019 Mar; 91(3):444-449. PubMed ID: 30229949
[TBL] [Abstract][Full Text] [Related]
20. FTO up-regulation induced by MYC suppresses tumour progression in Epstein-Barr virus-associated gastric cancer.
Xu YY; Li T; Shen A; Bao XQ; Lin JF; Guo LZ; Meng Q; Ruan DY; Zhang QH; Zuo ZX; Zeng ZL
Clin Transl Med; 2023 Dec; 13(12):e1505. PubMed ID: 38082402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
